Cargando…

In vivo targeting capacities of different nanoparticles to prostate tissues based on a mouse model of chronic bacterial prostatitis

Chronic bacterial prostatitis usually occurs in men and seriously affects the quality of life of patients. The efficacy of chronic bacterial prostatitis treatment is limited by the difficulty for free drugs (e.g., antibiotics) to penetrate the prostate epithelium and target inflammatory tissues. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Ruimin, Yang, Yang, Song, Guojing, Zhao, Fuhan, Chen, Saipeng, Zhou, Zhansong, Zheng, Jun, Shen, Wenhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582453/
https://www.ncbi.nlm.nih.gov/pubmed/36277385
http://dx.doi.org/10.3389/fbioe.2022.1021385
_version_ 1784812840783183872
author Hu, Ruimin
Yang, Yang
Song, Guojing
Zhao, Fuhan
Chen, Saipeng
Zhou, Zhansong
Zheng, Jun
Shen, Wenhao
author_facet Hu, Ruimin
Yang, Yang
Song, Guojing
Zhao, Fuhan
Chen, Saipeng
Zhou, Zhansong
Zheng, Jun
Shen, Wenhao
author_sort Hu, Ruimin
collection PubMed
description Chronic bacterial prostatitis usually occurs in men and seriously affects the quality of life of patients. The efficacy of chronic bacterial prostatitis treatment is limited by the difficulty for free drugs (e.g., antibiotics) to penetrate the prostate epithelium and target inflammatory tissues. The advent of nanotechnology offers the possibility to address this issue, such as the development of targeted nanoparticle delivery strategies that may overcome these important limitations. The physicochemical properties of nanoparticles, such as particle size, shape and surface modification ligands, determine their targeting effectiveness. In this study, nanoparticles with different physicochemical properties were prepared to explore and confirm their targeting capacities to inflammatory prostate tissues of chronic bacterial prostatitis, focusing on the effects of size and different modification ligands on the targeting performance. In vivo and ex vivo imaging results verified that folic acid-modified nanoparticles with a particle size of 180–190 nm via tail intravenous injection had the optimal targeting efficiency to prostate tissues. Our results provide an experimental basis and reference value for targeted therapy of prostate-related diseases with nanotechnology in the future.
format Online
Article
Text
id pubmed-9582453
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95824532022-10-21 In vivo targeting capacities of different nanoparticles to prostate tissues based on a mouse model of chronic bacterial prostatitis Hu, Ruimin Yang, Yang Song, Guojing Zhao, Fuhan Chen, Saipeng Zhou, Zhansong Zheng, Jun Shen, Wenhao Front Bioeng Biotechnol Bioengineering and Biotechnology Chronic bacterial prostatitis usually occurs in men and seriously affects the quality of life of patients. The efficacy of chronic bacterial prostatitis treatment is limited by the difficulty for free drugs (e.g., antibiotics) to penetrate the prostate epithelium and target inflammatory tissues. The advent of nanotechnology offers the possibility to address this issue, such as the development of targeted nanoparticle delivery strategies that may overcome these important limitations. The physicochemical properties of nanoparticles, such as particle size, shape and surface modification ligands, determine their targeting effectiveness. In this study, nanoparticles with different physicochemical properties were prepared to explore and confirm their targeting capacities to inflammatory prostate tissues of chronic bacterial prostatitis, focusing on the effects of size and different modification ligands on the targeting performance. In vivo and ex vivo imaging results verified that folic acid-modified nanoparticles with a particle size of 180–190 nm via tail intravenous injection had the optimal targeting efficiency to prostate tissues. Our results provide an experimental basis and reference value for targeted therapy of prostate-related diseases with nanotechnology in the future. Frontiers Media S.A. 2022-10-06 /pmc/articles/PMC9582453/ /pubmed/36277385 http://dx.doi.org/10.3389/fbioe.2022.1021385 Text en Copyright © 2022 Hu, Yang, Song, Zhao, Chen, Zhou, Zheng and Shen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Hu, Ruimin
Yang, Yang
Song, Guojing
Zhao, Fuhan
Chen, Saipeng
Zhou, Zhansong
Zheng, Jun
Shen, Wenhao
In vivo targeting capacities of different nanoparticles to prostate tissues based on a mouse model of chronic bacterial prostatitis
title In vivo targeting capacities of different nanoparticles to prostate tissues based on a mouse model of chronic bacterial prostatitis
title_full In vivo targeting capacities of different nanoparticles to prostate tissues based on a mouse model of chronic bacterial prostatitis
title_fullStr In vivo targeting capacities of different nanoparticles to prostate tissues based on a mouse model of chronic bacterial prostatitis
title_full_unstemmed In vivo targeting capacities of different nanoparticles to prostate tissues based on a mouse model of chronic bacterial prostatitis
title_short In vivo targeting capacities of different nanoparticles to prostate tissues based on a mouse model of chronic bacterial prostatitis
title_sort in vivo targeting capacities of different nanoparticles to prostate tissues based on a mouse model of chronic bacterial prostatitis
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582453/
https://www.ncbi.nlm.nih.gov/pubmed/36277385
http://dx.doi.org/10.3389/fbioe.2022.1021385
work_keys_str_mv AT huruimin invivotargetingcapacitiesofdifferentnanoparticlestoprostatetissuesbasedonamousemodelofchronicbacterialprostatitis
AT yangyang invivotargetingcapacitiesofdifferentnanoparticlestoprostatetissuesbasedonamousemodelofchronicbacterialprostatitis
AT songguojing invivotargetingcapacitiesofdifferentnanoparticlestoprostatetissuesbasedonamousemodelofchronicbacterialprostatitis
AT zhaofuhan invivotargetingcapacitiesofdifferentnanoparticlestoprostatetissuesbasedonamousemodelofchronicbacterialprostatitis
AT chensaipeng invivotargetingcapacitiesofdifferentnanoparticlestoprostatetissuesbasedonamousemodelofchronicbacterialprostatitis
AT zhouzhansong invivotargetingcapacitiesofdifferentnanoparticlestoprostatetissuesbasedonamousemodelofchronicbacterialprostatitis
AT zhengjun invivotargetingcapacitiesofdifferentnanoparticlestoprostatetissuesbasedonamousemodelofchronicbacterialprostatitis
AT shenwenhao invivotargetingcapacitiesofdifferentnanoparticlestoprostatetissuesbasedonamousemodelofchronicbacterialprostatitis